Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials

Overview

Journal Adv Ther

Date 2025 Jan 23

PMID 39847314

Authors

Khashayar Azimpour

Patricia Dorling

Irene Koulinska

Swati Kunduri

Zhiyi Lan

Julia Poritz

Gabriel Tremblay

Angie Raad-Faherty

Affiliations

Soon will be listed here.

Abstract

Introduction: Fabry disease (FD) is a rare lysosomal storage disorder that is associated with pain and progressive damage to the renal, cardiac, and cerebrovascular systems. Enzyme replacement therapy (ERT) is one of the treatment options for FD and the most recently approved ERT agent, pegunigalsidase alfa, has shown clinical efficacy in three phase 3 clinical trials of adults with FD: BALANCE, BRIDGE, and BRIGHT. Recent published guidelines support the mapping of health utility state data to the EuroQol-5 Dimension-3 Level (EQ-5D-3L) index to align with the preferred methodology used by the National Institute for Health and Care Excellence (NICE). Therefore, the primary objective of this study was to estimate EQ-5D-3L values in clinical trials of pegunigalsidase alfa for FD for future cost-utility analyses.

Methods: A mixed effects model was developed to predict values derived from EQ-5D-3L for the following health states used in cost-utility analyses: no Fabry clinical event (FCE)/no pain-related adverse event (AE), pain-related AE, cardiac FCE, cerebrovascular FCE, and renal FCE.

Results: The baseline EQ-5D-3L utility value had a statistically significant (p < 0.0001) impact on utility values, whereas study, age, sex, disease type, treatment arm, kidney function, and serious AE were not statistically significant. Health state utility values with 95% confidence intervals (CI) for the final model were as follows: no FCE/no pain-related AE, 0.8005 (0.7675, 0.8334); pain-related AE, 0.7737 (0.7262, 0.8211); cardiac FCE, 0.7189 (0.6274, 0.8103); cerebrovascular FCE, 0.7923 (0.6633, 0.9212); and renal FCE, 0.6881 (0.3887, 0.9874).

Conclusions: The utility values generated by the present study are generally in line with EQ-5D values in the FD literature and can be used to inform both economic evaluations and our understanding of the impact that FD has on quality of life.

Trial Registration: NCT03018730, NCT02795676, NCT03180840.

References

Miners A, Holmes A, Sherr L, Jenkinson C, Macdermot K . Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res. 2002; 11(2):127-33. DOI: 10.1023/a:1015009210639. View

Ubel P, Loewenstein G, Hershey J, Baron J, Mohr T, Asch D . Do nonpatients underestimate the quality of life associated with chronic health conditions because of a focusing illusion?. Med Decis Making. 2001; 21(3):190-9. DOI: 10.1177/0272989X0102100304. View

Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View

Jovanovic A, Miller-Hodges E, Castriota F, Takyar S, Howitt H, Ayodele O . A systematic literature review on the health-related quality of life and economic burden of Fabry disease. Orphanet J Rare Dis. 2024; 19(1):181. PMC: 11062018. DOI: 10.1186/s13023-024-03131-y. View

Wang A, Rand K, Yang Z, Brooks R, Busschbach J . The remarkably frequent use of EQ-5D in non-economic research. Eur J Health Econ. 2021; 23(6):1007-1014. PMC: 9304056. DOI: 10.1007/s10198-021-01411-z. View

Ortiz A, Germain D, Desnick R, Politei J, Mauer M, Burlina A . Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018; 123(4):416-427. DOI: 10.1016/j.ymgme.2018.02.014. View

Katsigianni E, Petrou P . A systematic review of economic evaluations of enzyme replacement therapy in Lysosomal storage diseases. Cost Eff Resour Alloc. 2022; 20(1):51. PMC: 9487102. DOI: 10.1186/s12962-022-00369-w. View

Arends M, Hollak C, Biegstraaten M . Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015; 10:77. PMC: 4501376. DOI: 10.1186/s13023-015-0296-8. View

Alava M, Pudney S, Wailoo A . Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. Pharmacoeconomics. 2022; 41(2):199-207. PMC: 9883358. DOI: 10.1007/s40273-022-01218-7. View

10.

Hoffmann B, Schwarz M, Mehta A, Keshav S . Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007; 5(12):1447-53. DOI: 10.1016/j.cgh.2007.08.012. View

11.

Germain D, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F . An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022; 137(1-2):49-61. DOI: 10.1016/j.ymgme.2022.07.010. View

12.

Rombach S, Hollak C, Linthorst G, Dijkgraaf M . Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013; 8:29. PMC: 3598841. DOI: 10.1186/1750-1172-8-29. View

13.

Torrance G . Utility approach to measuring health-related quality of life. J Chronic Dis. 1987; 40(6):593-603. DOI: 10.1016/0021-9681(87)90019-1. View

14.

Addington-Hall J, Kalra L . Who should measure quality of life?. BMJ. 2001; 322(7299):1417-20. PMC: 1120479. DOI: 10.1136/bmj.322.7299.1417. View

15.

Arends M, Korver S, Hughes D, Mehta A, Hollak C, Biegstraaten M . Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2017; 41(1):141-149. PMC: 5786653. DOI: 10.1007/s10545-017-0095-6. View

16.

Svarstad E, Marti H . The Changing Landscape of Fabry Disease. Clin J Am Soc Nephrol. 2020; 15(4):569-576. PMC: 7133143. DOI: 10.2215/CJN.09480819. View

17.

Lenders M, Brand E . Fabry Disease: The Current Treatment Landscape. Drugs. 2021; 81(6):635-645. PMC: 8102455. DOI: 10.1007/s40265-021-01486-1. View

18.

Linhart A, Dostalova G, Nicholls K, West M, Tondel C, Jovanovic A . Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023; 18(1):332. PMC: 10589982. DOI: 10.1186/s13023-023-02937-6. View

19.

Wallace E, Goker-Alpan O, Wilcox W, Holida M, Bernat J, Longo N . Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2023; 61(6):520-530. PMC: 11137442. DOI: 10.1136/jmg-2023-109445. View

20.

Winter Y, Hilz M, Beuschlein F, Tsukimura T, Seifritz E, Lenders M . Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study. Mol Genet Metab. 2023; 140(3):107692. DOI: 10.1016/j.ymgme.2023.107692. View